Clinical management of a pituitary gland metastasis from clear cell renal cell carcinoma

Fassett, 2004, Metastases to the pituitary gland, Neurosurg Focus, 16, 1, 10.3171/foc.2004.16.4.9

Ravnik, 2016, Hypophyseal metastases: a report of three cases and literature review, Neurol Neurochir Pol, 50, 511, 10.1016/j.pjnns.2016.08.007

McCormick, 1989, Metastatic carcinoma to the pituitary gland, Br J Neurosurg, 3, 71, 10.3109/02688698909001028

Komninos, 2004, Tumors metastatic to the pituitary gland: case report and literature review, J Clin Endocrinol Metab, 89, 574, 10.1210/jc.2003-030395

He, 2015, Metastatic involvement of the pituitary gland: a systematic review with pooled individual patient data analysis, Pituitary, 18, 159, 10.1007/s11102-014-0552-2

Ravnik, 2016, Hypophyseal metastases: a report of three cases and literature review, Neurol Neurochir Pol, 50, 511, 10.1016/j.pjnns.2016.08.007

Gopan, 2007, Symptomatic pituitary metastases from renal cell carcinoma, Pituitary, 10, 251, 10.1007/s11102-007-0047-5

Kramer, 2010, Pituitary gland metastasis from renal cell carcinoma presented as a non-functioning macroadenoma, Arq Bras Endocrinol Metab, 54, 498, 10.1590/S0004-27302010000500011

Bianchi, 2012, Distribution of metastatic sites in renal cell carcinoma: a population-based analysis, Ann Oncol, 23, 973, 10.1093/annonc/mdr362

Shuch, 2008, Brain metastasis from renal cell carcinoma: presentation, recurrence, and survival, Cancer, 113, 1641, 10.1002/cncr.23769

Motzer, 2009, Overall survival and updated results for sunitinib compared with interferon alfa in patients with metastatic renal cell carcinoma, J Clin Oncol, 27, 3584, 10.1200/JCO.2008.20.1293

Gore, 2009, Safety and efficacy of sunitinib for metastatic renal-cell carcinoma: an expanded-access trial, Lancet Oncol, 10, 757, 10.1016/S1470-2045(09)70162-7

Grassi, 2016, Clinical impact of pancreatic metastases from renal cell carcinoma: a multicenter retrospective analysis, PLoS One, 11, e0151662, 10.1371/journal.pone.0151662

Santini, 2016, Risk of recurrence and conditional survival in complete responders treated with TKIs plus or less locoregional therapies for metastatic renal cell carcinoma, Oncotarget, 7, 33381, 10.18632/oncotarget.8302

Kalra, 2016, Prognosis of patients with metastatic renal cell carcinoma and pancreatic metastases, BJU Int, 117, 761, 10.1111/bju.13185

Grassi, 2013, Prognostic role of pancreatic metastases from renal cell carcinoma: results from an Italian center, Clin Genitourin Cancer, 11, 484, 10.1016/j.clgc.2013.04.022

Chrom, 2018, Prognostic significance of pancreatic metastases from renal cell carcinoma in patients treated with tyrosine kinase inhibitors, Anticancer Res, 38, 359

Sun, 2018, The development of brain metastases in patients with renal cell carcinoma: epidemiologic trends, survival, and clinical risk factors using a population-based cohort, Eur Urol Focus, 5, S2405

Santoni, 2015, Sunitinib, pazopanib or sorafenib for the treatment of patients with late relapsing metastatic renal cell carcinoma, J Urol, 193, 41, 10.1016/j.juro.2014.07.011

Chevreau, 2014, A phase II trial of sunitinib in patients with renal cell cancer and untreated brain metastases, Clin Genitourin Cancer, 12, 50, 10.1016/j.clgc.2013.09.008

Choi, 2017, Prognostic factors for survival of patients with synchronous or metachronous brain metastasis of renal cell carcinoma, Clin Genitourin Cancer, 15, 717, 10.1016/j.clgc.2017.05.010

Wendel, 2017, Longo R1 pituitary metastasis from renal cell carcinoma: description of a case report, Am J Case Rep, 18, 7, 10.12659/AJCR.901032